QUAD is marketed by MEDVi as a sublingual, four-drug cocktail for erectile dysfunction, combining three well-known PDE5 inhibitors—sildenafil, tadalafil, and…
Read More
MEDVi’s Meteoric AI-Fueled Ascent Faces Scrutiny Amidst FDA Warnings, Allegations of Deceptive Marketing, and Multiple Lawsuits
A telehealth startup, MEDVi, recently lauded by The New York Times as a prime example of an AI-driven billion-dollar enterprise,…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
The digital health company MEDVi, recently spotlighted in an April 2 New York Times profile that depicted CEO Matthew Gallagher…
Read More
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric Growth
In an era increasingly shaped by the transformative power of artificial intelligence, a Los Angeles-based telehealth startup, MEDVi, has captured…
Read More
